These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 19805378)
1. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Follo MY; Finelli C; Mongiorgi S; Clissa C; Bosi C; Testoni N; Chiarini F; Ramazzotti G; Baccarani M; Martelli AM; Manzoli L; Martinelli G; Cocco L Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16811-6. PubMed ID: 19805378 [TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492 [TBL] [Abstract][Full Text] [Related]
3. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771 [TBL] [Abstract][Full Text] [Related]
4. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693 [TBL] [Abstract][Full Text] [Related]
5. An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. Cocco L; Finelli C; Mongiorgi S; Clissa C; Russo D; Bosi C; Quaranta M; Malagola M; Parisi S; Stanzani M; Ramazzotti G; Mariani GA; Billi AM; Manzoli L; Follo MY J Leukoc Biol; 2015 Nov; 98(5):769-80. PubMed ID: 25977289 [TBL] [Abstract][Full Text] [Related]
6. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS. Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275 [TBL] [Abstract][Full Text] [Related]
11. Phosphoinositide phospholipase Cbeta1 (PI-PLCbeta1) gene in myelodysplastic syndromes and cytogenetically normal acute myeloid leukemia: not a deletion, but increased PI-PLCbeta1 expression is an independent prognostic factor. Damm F; Lange K; Heuser M; Oberacker T; Morgan M; Wagner K; Krauter J; Schlegelberger B; Ganser A; Göhring G J Clin Oncol; 2010 Aug; 28(22):e384-7; author reply e388-9. PubMed ID: 20516454 [No Abstract] [Full Text] [Related]
12. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Filì C; Malagola M; Follo MY; Finelli C; Iacobucci I; Martinelli G; Cattina F; Clissa C; Candoni A; Fanin R; Gobbi M; Bocchia M; Defina M; Spedini P; Skert C; Manzoli L; Cocco L; Russo D Clin Cancer Res; 2013 Jun; 19(12):3297-308. PubMed ID: 23596104 [TBL] [Abstract][Full Text] [Related]
13. Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation. Mongiorgi S; Follo MY; Yang YR; Ratti S; Manzoli L; McCubrey JA; Billi AM; Suh PG; Cocco L Curr Pharm Des; 2016; 22(16):2345-8. PubMed ID: 26916022 [TBL] [Abstract][Full Text] [Related]
14. Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia. Ratti S; Mongiorgi S; Rusciano I; Manzoli L; Follo MY Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118649. PubMed ID: 31954103 [TBL] [Abstract][Full Text] [Related]
16. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia. Lo Vasco VR; Calabrese G; Manzoli L; Palka G; Spadano A; Morizio E; Guanciali-Franchi P; Fantasia D; Cocco L Leukemia; 2004 Jun; 18(6):1122-6. PubMed ID: 15085153 [TBL] [Abstract][Full Text] [Related]
17. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822 [TBL] [Abstract][Full Text] [Related]
18. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Follo MY; Finelli C; Bosi C; Martinelli G; Mongiorgi S; Baccarani M; Manzoli L; Blalock WL; Martelli AM; Cocco L Leukemia; 2008 Jan; 22(1):198-200. PubMed ID: 17625605 [No Abstract] [Full Text] [Related]
19. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922 [TBL] [Abstract][Full Text] [Related]
20. The euphoria of hypomethylating agents in MDS and AML: is it justified? Sekeres MA Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]